These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 21508859)

  • 1. Inhibition of cytochrome P450 3A by clarithromycin uniformly affects the pharmacokinetics and pharmacodynamics of oxycodone in young and elderly volunteers.
    Liukas A; Hagelberg NM; Kuusniemi K; Neuvonen PJ; Olkkola KT
    J Clin Psychopharmacol; 2011 Jun; 31(3):302-8. PubMed ID: 21508859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Grapefruit juice enhances the exposure to oral oxycodone.
    Nieminen TH; Hagelberg NM; Saari TI; Neuvonen M; Neuvonen PJ; Laine K; Olkkola KT
    Basic Clin Pharmacol Toxicol; 2010 Oct; 107(4):782-8. PubMed ID: 20406214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone.
    Nieminen TH; Hagelberg NM; Saari TI; Pertovaara A; Neuvonen M; Laine K; Neuvonen PJ; Olkkola KT
    Anesthesiology; 2009 Jun; 110(6):1371-8. PubMed ID: 19417618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodone.
    Grönlund J; Saari T; Hagelberg N; Martikainen IK; Neuvonen PJ; Olkkola KT; Laine K
    J Clin Pharmacol; 2010 Jan; 50(1):101-8. PubMed ID: 19755414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The hypoalgesic effect of oxycodone in human experimental pain models in relation to the CYP2D6 oxidation polymorphism.
    Zwisler ST; Enggaard TP; Noehr-Jensen L; Pedersen RS; Mikkelsen S; Nielsen F; Brosen K; Sindrup SH
    Basic Clin Pharmacol Toxicol; 2009 Apr; 104(4):335-44. PubMed ID: 19281600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S-ketamine.
    Hagelberg NM; Peltoniemi MA; Saari TI; Kurkinen KJ; Laine K; Neuvonen PJ; Olkkola KT
    Eur J Pain; 2010 Jul; 14(6):625-9. PubMed ID: 19897389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites.
    Lalovic B; Kharasch E; Hoffer C; Risler L; Liu-Chen LY; Shen DD
    Clin Pharmacol Ther; 2006 May; 79(5):461-79. PubMed ID: 16678548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study.
    Grönlund J; Saari TI; Hagelberg NM; Neuvonen PJ; Laine K; Olkkola KT
    Clin Drug Investig; 2011; 31(3):143-53. PubMed ID: 21142269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.
    Heiskanen T; Olkkola KT; Kalso E
    Clin Pharmacol Ther; 1998 Dec; 64(6):603-11. PubMed ID: 9871425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers.
    Kapil R; Nolting A; Roy P; Fiske W; Benedek I; Abramowitz W
    Clin Ther; 2004 Dec; 26(12):2015-25. PubMed ID: 15823765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life.
    Saari TI; Laine K; Leino K; Valtonen M; Neuvonen PJ; Olkkola KT
    Clin Pharmacol Ther; 2006 Nov; 80(5):502-8. PubMed ID: 17112806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.
    Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
    Br J Pharmacol; 2010 Jun; 160(4):907-18. PubMed ID: 20590587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Voriconazole drastically increases exposure to oral oxycodone.
    Hagelberg NM; Nieminen TH; Saari TI; Neuvonen M; Neuvonen PJ; Laine K; Olkkola KT
    Eur J Clin Pharmacol; 2009 Mar; 65(3):263-71. PubMed ID: 18836708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety.
    Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
    Br J Pharmacol; 2010 Jun; 160(4):919-30. PubMed ID: 20590588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.
    Jaakkola T; Backman JT; Neuvonen M; Neuvonen PJ
    Clin Pharmacol Ther; 2005 May; 77(5):404-14. PubMed ID: 15900286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity.
    Kharasch ED; Hoffer C; Walker A; Sheffels P
    Clin Pharmacol Ther; 2003 Mar; 73(3):199-208. PubMed ID: 12621385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of itraconazole on the pharmacokinetics and pharmacodynamics of intravenously and orally administered oxycodone.
    Saari TI; Grönlund J; Hagelberg NM; Neuvonen M; Laine K; Neuvonen PJ; Olkkola KT
    Eur J Clin Pharmacol; 2010 Apr; 66(4):387-97. PubMed ID: 20076952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elimination of intravenous oxycodone in the elderly: a pharmacokinetic study in postoperative orthopaedic patients of different age groups.
    Liukas A; Kuusniemi K; Aantaa R; Virolainen P; Neuvonen M; Neuvonen PJ; Olkkola KT
    Drugs Aging; 2011 Jan; 28(1):41-50. PubMed ID: 21174486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect.
    Varis T; Kivistö KT; Backman JT; Neuvonen PJ
    Clin Pharmacol Ther; 2000 Nov; 68(5):487-94. PubMed ID: 11103751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
    Kharasch ED; Walker A; Hoffer C; Sheffels P
    Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.